RxDoctor Payments Data

Debra Buchan, MD

Internal Medicine · Manlius, NYNPI 1689618498

Payments from drug & device makers

$2,854in general payments, 2019–2025

Across 166 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$420
  • AbbVie$353
  • Lilly USA, LLC$268
  • GSK$258
  • Novo Nordisk$235
  • Astellas Pharma US Inc$217
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$2,77697%
  • Education$783%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,854 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$111,459
Medicare patients
235
Services billed
1,545

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$126,810
EliquisApixaban77$126,577
TrulicityDulaglutide35$75,712
JardianceEmpagliflozin31$39,951
Trelegy ElliptaFluticasone/Umeclidin/Vilanter26$29,886
XareltoRivaroxaban15$22,870
Breo ElliptaFluticasone/Vilanterol38$19,590
Spiriva HandihalerTiotropium Bromide12$6,047
Arnuity ElliptaFluticasone Furoate11$5,811
Levothyroxine Sodium313$5,121
Fluticasone-SalmeterolFluticasone Propion/Salmeterol29$4,575
Albuterol Sulfate HfaAlbuterol Sulfate109$4,511
Atorvastatin Calcium428$4,391
Losartan Potassium337$4,149
Amlodipine Besylate382$2,588

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$235$126,81084 claims
PfizerEliquis$420$126,57777 claims
Lilly USA, LLCTrulicity$268$75,71235 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$258$55,28775 claims
Boehringer IngelheimJardiance$102$39,95131 claims
Johnson & JohnsonXarelto$29$22,87015 claims
AbbVieSynthroid$353$2,29931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Manlius

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →